anayamalik, Author at European Medical Journal - Page 61 of 120

Women’s Body Image After Mastectomy Reveal Deep Psychosocial Impact

A new study exploring women’s body image after mastectomy sheds light on the complex emotional and psychosocial challenges these patients face during and after breast cancer treatment.

Why Delirium Prediction Models Often Fail Doctors

Delirium remains a critical yet often underrecognized condition in acute care settings with direct links to increased mortality and extended hospital stays.

Immunotherapy After Surgery May Reduce HNSCC Recurrence: ASCO 2025

Adding nivolumab to postoperative chemoradiotherapy may reduce the likelihood of recurrence in patients with resected, high-risk head and neck squamous cell carcinoma (HNSCC), according to results from the Phase III NIVOPOSTOP trial presented at the 2025 ASCO Annual Meeting.

PD-L1-Positive TNBC Sees Slower Disease Growth: ASCO 2025

Patients with unresectable, locally advanced or metastatic PD-L1-positive triple-negative breast cancer (TNBC) experienced longer progression-free survival when treated with sacituzumab govitecan and pembrolizumab, compared to the current standard of chemotherapy plus pembrolizumab, according to new findings presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

β-Lactams Outperform Vancomycin in MSSA Treatment

IN a new meta-analysis, β-lactam antibiotics demonstrated significantly faster clinical response times than vancomycin in patients with methicillin-sensitive Staphylococcus aureus (MSSA) bloodstream infections, suggesting a potential shift in first-line treatment choices.

HER2-Targeted Therapy Extends Gastric Cancer Survival: ASCO 2025

Second-line treatment with trastuzumab deruxtecan has been shown to extend overall survival by more than 3 months in patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma (GEJA) following progression on first-line therapy, according to Phase III data from the DESTINY-Gastric04 trial presented at the ASCO 2025 Annual Meeting.

Earlier Geriatric Assessment Improves Hip Fracture Outcomes

Early geriatric assessments in older adults with hip fractures are strongly associated with improved recovery, reduced hospital stays, and lower complication rates, according to a new systematic review.

Vagus Nerve Stimulation Linked to Quality of Life Gains in Epilepsy

Vagus nerve stimulation (VNS) not only reduces seizures in patients with epilepsy but also leads to early and sustained improvements in mental health, sleep, and quality of life, according to a new multicenter cohort study.

ES-SCLC Maintenance Outcomes from IMforte Trial: ASCO 2025

First-line maintenance treatment with lurbinectedin and atezolizumab significantly improves survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC), according to primary results from the global Phase III IMforte trial presented at ASCO 2025.

New Oral Therapy Doubles PFS in ESR1+ Breast Cancer: ASCO 2025

A NEW oral therapy may significantly delay disease progression in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, according to results presented at the 2025 ASCO Annual Meeting.